drugset / Trial / NCT00347503

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

NCT00347503

Phase 4 Completed Innovative Medical
RandomizedParallel-groupSingle-blindTreatment

Summary

Evaluation of the aqueous concentrations of 2 topical NSAIDS as well as the PGE2 inhibition in human patients.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bromfenac Other / unclassified 0.09 % Topical
Subject Ketorolac Other / unclassified 0.4 % Topical

Indications